<DOC>
	<DOCNO>NCT02870972</DOCNO>
	<brief_summary>This 2-part study evaluate safety efficacy oral treatment , BCX7353 , prevent angioedema attack subject hereditary angioedema ( HAE ) . In Part 1 study , eligible subject randomize receive oral BCX7353 placebo 4 week . Assuming successful completion Part 1 , additional subject randomize Part 2 one 2 low dos BCX7353 placebo . The study compare number acute attack treatment group , well number clinical pharmacologic outcome , safety tolerability dose BCX7353 compare placebo .</brief_summary>
	<brief_title>Efficacy Safety BCX7353 Prevent Angioedema Attacks Subjects With Hereditary Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>Key A clinical diagnosis HAE type I II Documented HAE attack within define calendar period Access acute attack medication Sexually active woman childbearing potential sexually active men must utilize effective contraception Key Women pregnant breastfeed Any clinical condition medical history would interfere subject 's safety ability participate study Use C1INH , androgens tranexamic acid prophylaxis HAE attack History current alcohol drug abuse Infection hepatitis B , hepatitis C HIV Participation investigational drug study currently within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>